百濟神州(688235.SH):與諾華製藥簽訂合作協議 涉及在研TIGIT抑制劑ociperlimab進行開發、生產和商業化的獨家許可
格隆匯12月20日丨百濟神州(688235.SH)公佈,近日,公司全資子公司 BeiGene Switzerland GmbH (“百濟瑞士”)與 Novartis Pharma AG(諾華製藥集團,“諾華製藥”)簽訂一份《選擇權、合作和許可協議》。根據《合作協議》,公司向諾華製藥授予一項獨家的、基於時間的選擇權,以使諾華製藥可以通過行使該選擇權獲得在美國、加拿大、墨西哥、歐盟成員國、英國、挪威、瑞士、冰島、列支敦士登、俄羅斯和日本對公司的在研TIGIT抑製劑 ociperlimab進行開發、生產和商業化的獨家許可。
根據《合作協議》,諾華製藥將向公司支付3億美元的首付款;如諾華製藥於限定期限內行使選擇權,則公司有資格根據《合作協議》的約定獲得6億或7億美元的額外付款,並在實現監管批准里程碑後,有資格獲得最高7.45 億美元的付款;在實現銷售里程碑後,有資格獲得最高11.5億美元的付款;且公司還有資格獲得分級許可使用費。
公吿顯示,ociperlimab是一款在研人源化IgG 1單克隆抗體,由公司自主研發並在全球範圍內進行開發。作為一款免疫檢查點候選藥物,ociperlimab 是當前開發進程中最先進的抗TIGIT抗體之一,具有完整的Fc功能。抑制 TIGIT靶點為從免疫抑制腫瘤微環境中拯救免疫細胞(例如T細胞、NK細胞和樹突狀細胞)提供了潛在的作用機制,以誘導有效的抗腫瘤免疫應答。TIGIT通路被認為可與PD-1協作,最大程度抑制效應腫瘤浸潤免疫細胞,並增強對抗PD-1療法的抵抗力。
此次交易系公司與諾華製藥就tislelizumab開展合作後,在雙方管線上就協同效應開展的進一步探索,並旨在加速ociperlimab的上市進程。這一多元化合作的達成有利於進一步夯實雙方共同構建的合作基礎,並有望對公司的持續經營產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.